Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|January 23, 2018
FDA Heads Back to Work, for Now
Author(s)Pharmaceutical Technology Editors
The latest continuing resolution funds the government for three weeks.
Advertisement
After a three-day government shutdown due to a budget stalemate in Congress, FDA and other government employees resumed work on Jan. 23, 2018. On Monday, Jan. 22, approximately 40% of the FDA staff was furloughed due to the lack of funding for operations.
On Jan. 22, Congress approved, and President Trump signed, a continuing resolution that will fund the government through Feb. 8, 2018. Congress also funded the Children’s Health Insurance Program for six years and delayed taxes on medical device sales.
The funding extension was enacted after Senate leadership agreed to address the future of the Deferred Action for Childhood Arrivals (DACA) program, a program for people brought to the United States as minors, that is central to contentious debate to the nation’s immigration policy.
The Congress and the administration have three weeks to agree on funding for the government for the 2018 fiscal year, and to discuss DACA.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement